Fecal microbiota transplantation enhances immunotherapy response in advanced kidney cancer

hcplive.com

Fecal microbiota transplantation improved immunotherapy response in advanced kidney cancer patients. The TACITO trial showed fecal microbiota transplantation led to longer progression-free survival and a higher objective response rate in patients with metastatic renal cell carcinoma receiving standard immunotherapy. The study also observed positive changes in gut microbiome diversity in the treatment group, suggesting a potential complementary strategy for improving cancer treatment outcomes.


With a significance score of 4.5, this news ranks in the top 3.3% of today's 33709 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Fecal microbiota transplantation enhances immunotherapy response in advanced kidney cancer | News Minimalist